Nuvectis Pharma, Inc. (NVCT) SEC Filings & Earnings Calls
EquiReason read 13 Nuvectis Pharma, Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-08-21 — Nuvectis Pharma established an 'at the market' offering program for up to $200M in common stock via Jefferies, with 3% commission. Terminated prior ATM program. Potential dilution .
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 653.3M
- P/E TTM
- —
- Dividend yield
- 0.0%
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
21 Aug 20268-K · 8.01Nuvectis Pharma established an 'at the market' offering program for up to $200M in common stock via Jefferies, with 3% commission. Terminated prior ATM program. Potential dilution for existing shareholders.open
Figures in the filing · each found in the filing text
| Registered securities amount · 2026-08-21 | $200M |
Risks flagged
Potential equity dilution from ATM program; no minimum sales requirement
“Company may offer and sell shares of its common stock from time to time through Jefferies; Jefferies is not required to sell any specific number or dollar amount”
Termination of prior ATM program suggests shift in financing strategy
“On July 20, 2026, the Company terminated its prior at-the-market offering program” · word for word
4 Aug 20268-K · 2.02Nuvectis Pharma reported Q2 2026 financial results; net loss increased to $7.0M from $6.3M; cash $22.2M; key event is in-licensing of ciprocopan and $115M follow-on offering.earningsopen
Figures in the filing · each found in the filing text
| Cash and cash equivalents · Q2-2026 | $22M | |
| Net loss · Q2-2026 | $-7M | |
| Research and development expenses · Q2-2026 | $5M | |
| General and administrative expenses · Q2-2026 | $3M | |
| Finance income · Q2-2026 | $200000.00 |
Risks flagged
Clinical-stage biotech with no approved products in the U.S.; reliance on regulatory success.
“U.S. regulatory efforts underway; IND submission expected in 4Q2026” · word for word
4 Aug 202610-QNuvectis Pharma completed a public offering raising ~$106.3M net and entered an exclusive worldwide license for two clinical-stage drug candidates from Haisco.open
Figures in the filing · each found in the filing text
| Cash and cash equivalents · Q2-2026 | $22M | |
| Net loss · Q2-2026 | $-7M | |
| Research and development expenses · Q2-2026 | $5M | |
| General and administrative expenses · Q2-2026 | $3M | |
| Accumulated deficit · Q2-2026 | $-113M | |
| Operating cash flow · H1-2026 | $-11M |
Risks flagged
Pre-revenue, history of losses, needs additional capital
“We have incurred losses since our inception and have not generated any revenue. We expect to incur continued losses for the foreseeable future and may never achieve or maintain profitability.” · word for word
Dependence on success of NXP100, NXP200, NXP900
“We are substantially dependent on the success of our product candidates, NXP100, NXP200 and NXP900.” · word for word
Clinical trial uncertainty
“Clinical trials are very expensive, time-consuming, and difficult to design and implement, and involve uncertain safety, tolerability, and efficacy outcomes.” · word for word
30 Jun 20268-K · 1.01, 8.01Nuvectis Pharma entered into an underwriting agreement for a firm commitment public offering of 5,000,000 shares at $20.00 per share, with expected net proceeds of ~$93 million.open
Risks flagged
Dilution risk from new share issuance.
“5,000,000 shares offered, plus option for 750,000 additional shares.”
29 Jun 20268-K · 8.01Nuvectis Pharma lowered the amount available under its Sales Agreement with Leerink Partners to $5 million and suspended further sales until a new prospectus is filed.open
Risks flagged
Suspension of ATM program may signal reduced access to equity capital or strategic shift.
“Company suspending the Sales Agreement Prospectus and will not make any sales unless a new prospectus is filed.”
23 Jun 20268-K · 1.01, 8.01Exclusive license from Haisco for two late-stage assets (Complement Factor B inhibitor, BRAF inhibitor) for $20M upfront, up to $1.4B milestones plus royalties. Expands pipeline into complement-mediated diseases and BRAF-mutated cancers.open
Risks flagged
Financing condition for effectiveness; company must secure sufficient capital to develop licensed products.
“License Agreement will become effective subject to certain financing conditions.” · word for word
5 May 20268-K · 2.02Nuvectis Pharma reports Q1 2026 net loss of $6.1M vs $5.3M YoY; cash $25.1M; NXP900 Phase 1b enrolling; expects preliminary data readout in summer 2026.earningsopen
Figures in the filing · each found in the filing text
| Cash and cash equivalents · Q1-2026 | $25M | -21% y/y |
| Net loss · Q1-2026 | $-6M | +15% y/y |
| Research and development expenses · Q1-2026 | $4M | +11% y/y |
| General and administrative expenses · Q1-2026 | $2M | +16% y/y |
| Finance income · Q1-2026 | $200000.00 | 0% y/y |
Risks flagged
Cash burn rate may require future financing; no revenue; clinical trial risk.
“Cash decreased from $31.6M to $25.1M in three months; net loss $6.1M.”
5 May 202610-QQ1 2026 net loss increased 13.5% YoY; cash burn accelerated; no revenue.earningsopen
Figures in the filing · each found in the filing text
| Cash and cash equivalents · Q1-2026 | $25M | -16% y/y |
| Net loss · Q1-2026 | $-6M | +14% y/y |
| Accumulated deficit · Q1-2026 | $-106M | +35% y/y |
| Operating cash flow · Q1-2026 | $-7M | +56% y/y |
Risks flagged
Cash runway limited to ~12 months
“Management believes that its existing cash and cash equivalents as of March 31, 2026 enable the Company to fund planned operations for at least 12 months following the issuance date of these condensed financial statements.” · word for word
No revenue, history of losses
“We have incurred losses since our inception and have not generated any revenue.” · word for word
Dependence on single product candidate NXP900
“We are substantially dependent on the success of our product candidate, NXP900.” · word for word
27 Apr 2026DEF 14AAnnual proxy statement; no material governance or compensation changes.open
Figures in the filing · each found in the filing text
| Cash and cash equivalents · FY2025 | $25M | |
| Net loss · FY2025 | $-6M | |
| Accumulated deficit · FY2025 | $-106M | |
| Operating cash flow · FY2025 | $-7M |
Risks flagged
No revenue, history of losses
“We have incurred losses since our inception and have not generated any revenue.”
Dependence on single product candidate NXP900
“We are substantially dependent on the success of our product candidate, NXP900.”
11 Feb 20268-K · 2.02Nuvectis Pharma reported FY2025 net loss of $26.4M (vs $19.0M in FY2024), R&D expenses $18.2M (+$5.3M YoY), G&A $9.4M (+$2.5M YoY). Cash $31.6M (up from $18.5M due to equity offering). No revenue; clinical-stage biotech with NXP900 Phase 1bearningsopen
Figures in the filing · each found in the filing text
| Cash and Cash Equivalents · FY2025 | $32M | +71% y/y |
| Net Loss · FY2025 | $-26M | +39% y/y |
| Research and Development Expenses · FY2025 | $18M | +41% y/y |
| General and Administrative Expenses · FY2025 | $9M | +36% y/y |
| Finance Income · FY2025 | $1M | +38% y/y |
Risks flagged
No revenue; pre-commercial stage with significant cash burn.
“Net loss $26.4M; R&D expenses $18.2M; no revenue reported.”
Dependence on NXP900 clinical trial success; Phase 1b data readouts in 2026 are binary events.
“NXP900 is the sole pipeline asset; Phase 1b program is enrolling.”
One-time license fees and stock-based compensation add volatility to expenses.
“Net loss for the 2025 fiscal year included $6.0 million in non-cash stock-based compensation and one-time license fees associated with milestone achievements of $2.4 million.” · word for word
11 Feb 202610-KAnnual report filed; no revenue, increased net loss, NXP800 development ceased.earningsopen
Figures in the filing · each found in the filing text
| Accumulated Deficit · FY2025 | $100M | |
| Full-time Employees · 2026-02-06 | 13 |
Risks flagged
Clinical failure risk
“We have not yet demonstrated our ability to successfully conduct or complete any clinical development program for our drug candidates.” · word for word
Financing risk
“We will require substantial additional funding. Raising additional capital may cause dilution to our existing stockholders.” · word for word
Regulatory approval risk
“Denial of or delay in our receipt of required regulatory approvals may prevent or delay commercialization of our current or future product candidates.” · word for word
4 Nov 20258-K · 2.02Nuvectis Pharma reported Q3 2025 financial results with net loss of $7.5M vs $4.2M YoY, cash $35.4M, and provided clinical updates on NXP900 Phase 1b program.earningsopen
Figures in the filing · each found in the filing text
| Cash and cash equivalents · Q3-2025 | $35M | +91% y/y |
| Net loss · Q3-2025 | $-8M | +79% y/y |
| Research and development expenses · Q3-2025 | $6M | +107% y/y |
| General and administrative expenses · Q3-2025 | $2M | +33% y/y |
| Interest income · Q3-2025 | $300000.00 | +50% y/y |
Risks flagged
Clinical-stage biotech with no approved products; high cash burn rate and reliance on financing.
“Net loss increased 79% YoY; R&D spend doubled; cash runway only into 3Q-2027.”
4 Nov 202510-QQuarterly report filed; net loss increased, NXP800 development ceased, NXP900 Phase 1b initiated.earningsopen
Figures in the filing · each found in the filing text
| Cash and Cash Equivalents · Q3-2025 | $35M | |
| Accumulated Deficit · Q3-2025 | $92M | |
| General and Administrative Expense · Q3-2025 | $2M | +31% y/y |
| Operating Cash Flow · 9M-2025 | $-12M | +23% y/y |
Risks flagged
Clinical failure risk
“We are substantially dependent on the success of our product candidate, NXP900.” · word for word
Financing risk
“We will require substantial additional capital to finance our operations and achieve our goals.” · word for word
Regulatory approval risk
“Denial of or delay in our receipt of required regulatory approvals may prevent or delay commercialization of our current or future product candidates.” · word for word
Nuvectis Pharma, Inc. — questions
- What did Nuvectis Pharma, Inc. file recently?
- 13 SEC filings in the last 12 months. Latest: 8-K on 2026-08-21 — Nuvectis Pharma established an 'at the market' offering program for up to $200M in common stock via Jefferies, with 3% commission. Terminated prior ATM program. Potential dilution for existing shareholders.
Every figure on this page comes from Nuvectis Pharma, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.